VRCA

SEC source: 0001209191-23-055527 · doc4.xml · nonDerivative · entry 2

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,226

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive.

SEC source: 0001209191-23-055542 · doc4.xml · nonDerivative · entry 2

Bonaccorso Joe · CIK 0001741973 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,392

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive.

SEC source: 0001209191-23-055534 · doc4.xml · nonDerivative · entry 2

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,257

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive.

SEC source: 0001209191-23-055528 · doc4.xml · nonDerivative · entry 2

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,090

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive.

SEC source: 0001209191-23-055531 · doc4.xml · nonDerivative · entry 1

Kohler Terry · CIK 0001872285 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,048

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

SEC source: 0001209191-23-055527 · doc4.xml · nonDerivative · entry 1

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,784

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

SEC source: 0001209191-23-055542 · doc4.xml · nonDerivative · entry 1

Bonaccorso Joe · CIK 0001741973 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,658

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

SEC source: 0001209191-23-055534 · doc4.xml · nonDerivative · entry 1

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,293

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

SEC source: 0001209191-23-055528 · doc4.xml · nonDerivative · entry 1

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181,648

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

SEC source: 0001209191-23-047524 · doc4.xml · nonDerivative · entry 1

Kohler Terry · CIK 0001872285 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered.

SEC source: 0001209191-23-047521 · doc4.xml · nonDerivative · entry 1

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,925

F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered.

SEC source: 0001209191-23-047523 · doc4.xml · nonDerivative · entry 1

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,789

F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered.

SEC source: 0001209191-23-047519 · doc4.xml · nonDerivative · entry 1

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,110

F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered.

SEC source: 0001209191-23-047518 · doc4.xml · nonDerivative · entry 1

Bonaccorso Joe · CIK 0001741973 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,238

F1 · shares: Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered.

SEC source: 0001415889-25-003233 · form4a-02062025_040208.xml · nonDerivative · entry 1

Kohler Terry · CIK 0001872285 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.

F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

SEC source: 0001415889-25-003232 · form4a-02062025_040206.xml · nonDerivative · entry 1

Hayes Christopher G. · CIK 0001805359 · CHIEF LEGAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,925

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.

F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

SEC source: 0001415889-25-003234 · form4a-02062025_040211.xml · nonDerivative · entry 1

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,110

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.

F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

SEC source: 0001415889-25-003231 · form4a-02062025_040204.xml · nonDerivative · entry 1

White Ted · CIK 0001741964 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278,789

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.

F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

SEC source: 0001415889-25-003230 · form4a-02062025_040201.xml · nonDerivative · entry 1

Bonaccorso Joe · CIK 0001741973 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,738

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale.

F2 · shares: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

F2 · balance_after: The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction.

SEC source: 0001209191-23-043255 · doc4.xml · nonDerivative · entry 1

Manning Paul B · CIK 0001494695 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,851,128

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: Reflects the Reporting Person's contribution of shares into the PBM 2022 Grantor Retained Annuity Trust. This transfer of shares constitutes a change in the form of beneficial ownership and was exempt from reporting.

F3 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse.

SEC source: 0001209191-23-043306 · doc4.xml · nonDerivative · entry 2

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,925

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-043304 · doc4.xml · nonDerivative · entry 2

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,110

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-043301 · doc4.xml · nonDerivative · entry 2

Bonaccorso Joe · CIK 0001741973 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,738

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-043297 · doc4.xml · nonDerivative · entry 2

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,789

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on July 21, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-043306 · doc4.xml · nonDerivative · entry 1

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,714

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.

SEC source: 0001209191-23-043304 · doc4.xml · nonDerivative · entry 1

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,809

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.

SEC source: 0001209191-23-043301 · doc4.xml · nonDerivative · entry 1

Bonaccorso Joe · CIK 0001741973 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,000

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.

SEC source: 0001209191-23-043297 · doc4.xml · nonDerivative · entry 1

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,466

F1 · shares: Represents restricted stock unit ("RSU") awards with performance based vesting, which were originally granted in 2019 and 2020. The RSUs vested 50% upon receipt of regulatory approval of the Issuer's new drug application for VP-102 for the treatment of molluscum, and the remaining 50% shall vest on July 21, 2024, subject to the Reporting Person's continuous service through each applicable date.

SEC source: 0001209191-23-036147 · doc4.xml · derivative · entry 1

Nguyen Diem · CIK 0001814338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-23-036151 · doc4.xml · derivative · entry 1

Ballaron Craig · CIK 0001779433 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-23-036149 · doc4.xml · derivative · entry 1

Eichenfield Lawrence · CIK 0001814892 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-23-036145 · doc4.xml · derivative · entry 1

PRYGOCKI MARK A SR · CIK 0001257544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2033-06-07

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-23-015503 · doc4.xml · derivative · entry 1

Kohler Terry · CIK 0001872285 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-015492 · doc4.xml · derivative · entry 1

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-015511 · doc4.xml · derivative · entry 1

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-015507 · doc4.xml · derivative · entry 1

Bonaccorso Joe · CIK 0001741973 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-23-015497 · doc4.xml · derivative · entry 1

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2033-02-28

F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001209191-22-041835 · doc4.xml · nonDerivative · entry 1

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,714

SEC source: 0001062993-22-015932 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,038,983

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-22-040616 · doc4.xml · nonDerivative · entry 1

Hayes Christopher G. · CIK 0001805359 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,214

SEC source: 0001209191-22-040608 · doc4.xml · nonDerivative · entry 1

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,466

SEC source: 0001209191-22-040600 · doc4.xml · nonDerivative · entry 1

Goldenberg Gary · CIK 0001741938 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,809

SEC source: 0001209191-22-040591 · doc4.xml · nonDerivative · entry 1

Stalfort John A III · CIK 0001709418 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,205

SEC source: 0001209191-22-040581 · doc4.xml · nonDerivative · entry 1

Manning Paul B · CIK 0001494695 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,651,128

F1 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse.

SEC source: 0001209191-23-011127 · doc4a.xml · nonDerivative · entry 1

White Ted · CIK 0001741964 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,466

F1 · shares: The original Form 4 inadvertently listed the incorrect number of shares purchased by the Reporting Person. This represents the correct number of shares.

SEC source: 0001209191-22-036293 · doc4.xml · derivative · entry 1

Nguyen Diem · CIK 0001814338 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-22-036300 · doc4.xml · derivative · entry 1

Ballaron Craig · CIK 0001779433 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-22-036298 · doc4.xml · derivative · entry 1

PRYGOCKI MARK A SR · CIK 0001257544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-22-036297 · doc4.xml · derivative · entry 1

Eichenfield Lawrence · CIK 0001814892 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,384

Underlying: Common Stock · 10,384 shares

Expires 2032-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 9, 2022 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date.

SEC source: 0001209191-22-013196 · doc4.xml · derivative · entry 1

Kohler Terry · CIK 0001872285 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-23

F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.